UCSF home page | About UCSF | UCSF Medical Center

Skip to TransPortal content

Enlarge Text
Click to increase the text size. Restore Text
Click to restore original text size. Reduce Text
Click to decrease the text size.


Decrease the text size \| Restore text size \| Increase the text size

N-methylpyridinium

In Vitro Substrates

* denotes drugs that can potentially be used for in vivo (clinical) studies of the designated transporter

Transporter	Synonyms	Km (μM)	Cell System	Reference
SLC22A2	OCT2	19	OCT2-expressing oocytes	Gorboulev, 1997
SLC22A2	OCT2	16	HEK293-OCT2	Busch, 1998
SLC22A3	OCT3	47	HRPE-OCT3	Wu, 2000
SLC47A1	MATE1	16	HEK293-MATE1	Otsuka, 2005
SLC47A2	MATE2K	93.5	HEK293-MATE2K	Masuda, 2006
SLC47A1	MATE1	100	HEK293-MATE1	Tanihara, 2007
SLC47A2	MATE2K	110	HEK293-MATE2K	Tanihara, 2007
SLC22A1	OCT1	21	MDCK II-OCT1	Bachmakov, 2008
SLC22A2	OCT2	19.5	HEK293-OCT2	Zolk, 2009
SLC22A2	OCT2	19.5	HEK293-OCT2	Zolk, 2009

* denotes drugs that can potentially be used for in vivo (clinical) studies of the designated transporter

Transporter	Synonyms	Inhibitor	IC50 (μM)	Ki (μM)	Substrate used	Cell System	Reference
SLC22A2	OCT2	N-methylpyridinium		2.4	Tetraethylammonium	OCT2-expressing oocytes	Gorboulev, 1997
SLC22A1	OCT1	N-methylpyridinium	30.4		YM155	HEK293-OCT1	Minematsu, 2010
SLC22A2	OCT2	N-methylpyridinium	4.42		YM155	HEK293-OCT2	Minematsu, 2010

No drug-drug interaction information.